Menu Global healthcare communications consultancy 90TEN, part of Envision Pharma Group, today announced its expansion to the US market and appointment of Kate Paxton as its US Head. Paxton will oversee projects with a number of current 90TEN and Envision Pharma Group clients, grow her US team of healthcare communications specialists, leverage the existing rich resources within the organization for US client needs, and showcase the agency and its unique culture and approach. “We are thrilled to have such an experienced and passionate professional like Kate join the growing 90TEN team,” said David Thompson, Chief Executive Officer, Envision Pharma Group. “Kate’s long history of building strategic and creative programs for healthcare clients of every size and scope – in addition to her deep understanding of how agencies grow and thrive – makes her ideally suited to lead 90TEN through this next, exciting phase.” Paxton has almost 30 years of experience in agency communications and healthcare, ranging from corporate communications, product comms, and advocacy relations – to celebrity campaigns and issues management. Prior to 90TEN, Paxton spent a year and a half at JPA Health, where she designed and led campaigns for several biotech companies focused on oncology and rare diseases, and almost 23 years at Ketchum, where she held multiple leadership positions, including Managing Director of London Health for over 2 years and Practice Director of Washington, D.C. Health for over 7 years. Campaigns that Paxton led have won multiple industry awards, including three Silver Anvils from the Public Relations Society of America and one Healthcare Campaign of the Year from PR Week. “I have been an admirer of 90TEN for many years and always respected how bold, creative, and effective their campaigns are,” Paxton said. “So, when the opportunity came to lead the US launch and rollout, maximize the incredible talent and resources that already exist, and work with the award-winning London team – all of whom are passionate about changing lives for the better – I jumped at the chance.” Based in London, 90TEN is one of the leading healthcare communications consultancies in Europe and works with half of the top 20 pharma companies in the world serving clients across Europe and North America. In 2020, it was named Communications Consultancy of the Year at both the Communiqué Awards and Sabre EMEA Awards. That same year, it became part of Envision Pharma Group – a global provider of evidence-based communication services and industry-leading technology solutions. Thompson added, “The US PR marketplace is highly competitive, but given the pairing of Envision’s footprint and deep scientific capabilities with 90TEN’s award-winning, behavioral science approach, we are confident that 90TEN US represents an exciting new offering for the American market.” Dot grid. Related news View all news Our growing presence in Japan and the Asia-Pacific region News/events Our growing presence in Japan and the Asia-Pacific region August 30, 2017 Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running News/events Envision Pharma Group wins “Best Original Research” prize at ISMPP for the second year running August 26, 2017 Envision Pharma Group announces the availability of Scopus citation counts in Datavision News/events Envision Pharma Group announces the availability of Scopus citation counts in Datavision April 24, 2017 Envision announces Altmetric attention data now available in Library™ scientific content management software News/events Envision announces Altmetric attention data now available in Library™ scientific content management software April 24, 2017 Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information News/events Envision Pharma Group launches Medinfo™ – a new purpose-built software solution for medical information March 20, 2017 iEnvision Contact us ISO/IEC 27001 Certification Twitter LinkedIn © 2001-2020 Envision Pharma Group. All rights reserved. Terms of use Privacy notice Cookies notice Privacy shield policy Modern slavery statement We use cookies on our website. By continuing to use this website, you consent to our use of cookies in accordance with our cookie policy. To learn more about cookies, how we use them, and how you can change your settings, please view our Cookies Notice Accept